Skip global navigation and go to header navigation

Skip global navigation and read the article

Skip global navigation and go to local navigation

Skip global navigation and go to footer navigation



Home > Corporate Profile > Business Field > Research and Development

Research and Development


Research and Development

Actively Promoting Overseas Clinical Trials of Our Own Original Products and the In-licensing of Drugs Proven Overseas Markets

A recent trend in R&D activities for new drugs is the growing importance of basic research due to advances in drug discovery technologies based on genome information and progress in molecular medicine. Concurrently, the development process has also evolved, becoming more sophisticated, complex and globalized.

Zeria is actively promoting international clinical trials of our own original compounds overseas. At the same time, we are strengthening our new drug pipeline by seeking opportunities for in-licensing drugs that have sales track records in overseas markets.

Zeria is working to develop original and highly safe and effective new drugs.

Targeting the Gastrointestinal Field and Oncology Field

Our ethical drug development targets the gastrointestinal field and oncology field.

We are promoting the domestic development of Z-215, a long-lasting proton pump inhibitor, and Z-213, a therapeutic agent for iron deficiency anemia, while undertaking Asian global clinical trials for Z-100, a therapeutic agent for cervical cancer.

Swiss-based Tillotts Pharma, a Zeria subsidiary, is promoting development that includes the development of TP05, a therapeutic agent for ulcerative colitis, in Europe and Canada and TP09, a treatment for familial adenomatous polyposis (FAP), in Europe and the United States.

In the future, we will continue to actively promote the overseas development of new drugs as well as steadily promote a number of drugs under development that are in the last phases of development in Japan. At the same time, we will enhance and strengthen our new drug pipeline that includes in-licensed products.

Cultivating Products That Will Be New Pillars

In the Consumer Healthcare business, we will undertake development centered on our OTC drugs to cultivate new national brands subsequent to the Chondroitin range and Hepalyse range.

We are also making efforts to commercialize original new products. These include Direct OTC drugs involving the development of ingredients with no proven record as ethical drugs in Japan into OTC products such as European herbal medicines and Rx-to-OTC switched products. As an example, we launched the European herbal medicine Prefemin, which is in-licensed from Max Zeller Söhne AG of Switzerland, as Japan’s first therapeutic agent for premenstrual syndrome (PMS) in September 2014.


Going forward, Zeria will actively make R&D investments in these priority fields while advancing the development of unique new products that contribute to the health of people throughout the world.

Research and Development Pipeline

UP DATE 2-Nov-17

1. Domestic

Stage Development
Code/ Generic
Name
Development Indications Classsification Origin
Phase III
(Asia Global Development)
Z-100 Zeria Cervical cancer Immunomodulator Original
Phase III Z-213/
Ferric carboxymaltose
Zeria Iron deficiency anemia Intravenous iron replacement In-licensed
Phase II
(Asia Global Development)
Z-360 Zeria Pancreatic cancer Gastrin CCK2 receptor antagonist Original
Launched in Japan
Launch Date Development Code/ Generic Name Development Indications Classsification Notes
18-May-17 Z-206/Mesalazine
Asacol® additional dosage and administration
Zeria
(co-development with Kyowa Hakko Kirin Co., Ltd)
Ulcerative Colitis Targeted local, colonic, anti-inflammatory with pH dependent controlled-release formulation Original (Tillotts Pharma AG)
29-Nov-16 Budesonide
Product name:Zentacort
AstraZeneca K.K. Crohn’s disease Glucocorticosteroid with controlled-release formulation In-licensed

2. Overseas

Stage Development Code/
Generic Name
Development Indications Classsification Origin
NDA filed
(China)
Z-206
Mesalazine
Zeria·Tillotts Pharma AG co-development Ulcerative colitis Targeted local, colonic, anti-inflammatory with pH dependent controlled-release formulation Original
(Tillotts Pharma AG)
Phase III
(Europe)
Z-338
Acotiamide
Zeria Functional dyspepsia Upper gastrointestinal motility modulator Original
Phase III
(Asia)
Z-100 Zeria Cervical cancer Immunomodulator Original
NDA filed
(Europe)
TP05
Mesalazine
Tillotts Pharma AG Ulcerative colitis Targeted local, colonic, anti-inflammatory with OPTICORE™ formulation Original (Tillotts Pharma AG)
Phase III
(Europe, US)
TP09
Eflornithine/Sulindac
Tillotts Pharma AG
(co-development with Cancer Prevention Pharmaceuticals, Inc.)
Familial adenomatous polyposis Polyamine biosynthesis suppression In-licensed
(Europe and Japan)
Phase II
completed

(North America)
Z-338
Acotiamide
Zeria Functional dyspepsia Upper gastrointestinal motility modulator Original
Phase II
(Asia)
Z-360 Zeria Pancreatic cancer Gastrin CCK2 receptor antagonist Original